Therapeutic Impact of Follistatin-Like 1 on Myocardial Ischemic Injury in Preclinical Models
Authors:
- 2 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 126 (14) , 1728-1738
Abstract
Background—: Acute coronary syndrome is a leading cause of death in developed countries. Follistatin-like 1 (FSTL1) is a myocyte-derived secreted protein that is upregulated in the heart in response to ischemic insult. Here, we investigated the therapeutic impact of FSTL1 on acute cardiac injury in small and large preclinical animal models of ischemia/reperfusion and dissected its molecular mechanism. Methods and Results—: Administration of human FSTL1 protein significantly attenuated myocardial infarct size in a mouse or pig model of ischemia/reperfusion, which was associated with a reduction of apoptosis and inflammatory responses in the ischemic heart. Administration of FSTL1 enhanced the phosphorylation of AMP-activated protein kinase in the ischemia/reperfusion–injured heart. In cultured cardiac myocytes, FSTL1 suppressed apoptosis in response to hypoxia/reoxygenation and lipopolysaccharide-stimulated expression of proinflammatory genes through its ability to activate AMP-activated protein kinase. Ischemia/reperfusion led to enhancement of bone morphogenetic protein-4 expression and Smad1/5/8 phosphorylation in the heart, and FSTL1 suppressed the increased phosphorylation of Smad1/5/8 in ischemic myocardium. Treating cardiac myocytes with FSTL1 abolished the bone morphogenetic protein-4–stimulated increase in apoptosis, Smad1/5/8 phosphorylation, and proinflammatory gene expression. In cultured macrophages, FSTL1 diminished lipopolysaccharide-stimulated expression of proinflammatory genes via activation of AMP-activated protein kinase and abolished bone morphogenetic protein-4–dependent induction of proinflammatory mediators. Conclusions—: Our data indicate that FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase– and bone morphogenetic protein-4–dependent mechanisms, suggesting that FSTL1 could represent a novel therapeutic target for post-myocardial infarction, acute coronary syndrome.Keywords
This publication has 45 references indexed in Scilit:
- FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expressionArthritis & Rheumatism, 2011
- Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overloadProceedings of the National Academy of Sciences, 2011
- Macrophage α1 AMP-activated Protein Kinase (α1AMPK) Antagonizes Fatty Acid-induced Inflammation through SIRT1Journal of Biological Chemistry, 2010
- Impact of a Single Intracoronary Administration of Adiponectin on Myocardial Ischemia/Reperfusion Injury in a Pig ModelCirculation: Cardiovascular Interventions, 2010
- Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich AssayClinical Chemistry, 2009
- Mesencephalic Astrocyte-Derived Neurotrophic Factor Is an Ischemia-Inducible Secreted Endoplasmic Reticulum Stress Response Protein in the HeartCirculation Research, 2008
- Expression of Follistatin-Related Genes Is Altered in Heart FailureEndocrinology, 2008
- Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the HeartCirculation, 2008
- Role of apoptosis in ventricular remodelingCurrent Heart Failure Reports, 2005
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003